The researchers compared the drugs to bupropion-naltrexone, the active ingredient in weight-loss drug Contrave, which was approved in 2014. A Novo Nordisk spokesperson noted that some of the ...
It outperformed Orexigen's Mysimba/Contrave weight loss drug, where around a quarter of patients in a phase 3 trial achieved the target. Semaglutide came out top of the analysis, with 63% of ...